Strategic Blueprint’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Strategic Blueprint’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-61	Closed	-$13.7K	–	581
2023 Q3	$13.7K	Hold	61	–	–	﹤0.01%	525
2023 Q2	$18.4K	Hold	61	–	–	﹤0.01%	533
2023 Q1	$19K	Hold	61	–	–	﹤0.01%	506
2022 Q4	$7.78K	Sell	61 -2	-3%	-$334	﹤0.01%	504
2022 Q3	$17K	Sell	63 -6	-9%	-$2.29K	﹤0.01%	485
2022 Q2	$31K	Sell	69 -63	-48%	-$44.5K	﹤0.01%	484
2022 Q1	$163K	Sell	132 -21	-14%	-$28.6K	0.02%	486
2021 Q4	$386K	Buy	+153	New	+$934K	0.05%	321

Other funds holding IRLA

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Strategic Blueprint's IRLA Position: Q4 2023 in Review

Strategic Blueprint sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2023, closing a stake of 61 shares — an estimated $13.7K sold.

Strategic Blueprint first reported a position in IRLA in Q4 2021 and held it in 8 quarters. The position peaked at $386K in Q4 2021. 42 funds tracked by Wall St. Rank hold IRLA as of Q4 2023.

Strategic Blueprint reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Strategic Blueprint sold 61 IRulya Therapeutics Inc. Common Stock shares in Q4 2023, an estimated $13.7K.
Strategic Blueprint first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Strategic Blueprint's IRulya Therapeutics Inc. Common Stock position peaked at $386K in Q4 2021.
42 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2023.

Based on Strategic Blueprint's 13F filing for Q4 2023, filed 25 Jan 2024.